Caladrix’s scientific platform centers on ATP-binding cassette (ABC) transporters. For Alzheimer’s Disease, a validated efflux mechanism responsible for clearing neurotoxic proteins, inflammatory molecules, and metabolites from brain tissue is in development. Unlike antibody therapies that rely on immune mechanisms and carry the risk of ARIA, Caladrix enhances a specific ABC-transporter function through small molecules. This non-immunologic, ARIA-free approach restores physiological protein clearance, reduces neuroinflammation, and reinstates cellular homeostasis. Human and animal data, along with genetic validation from over 730,000 individuals, affirmed the target ABC-transporter as a causal and protective factor in Alzheimer’s disease.

Caladrix’s lead clinical candidate, C-001, is an orally available ABC modulator targeting early-stage Alzheimer’s disease.
The development program is informed by preclinical efficacy data, translational biomarker findings, and human proof-of-concept studies. C-001 is entering a Phase 1 trial in 2H 2026.
Platform approach: New chemical entities are in development for AD and other diseases, including modified-release oral formulations for global scalability and patient adherence.

Stay informed on Caladrix’s clinical milestones, scientific publications, investor updates, and participation in major conferences